Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy

QuestionIs the novel Kv7.2/Kv7.3 potassium channel opener XEN1101 effective in reducing the monthly seizure frequency in adults experiencing focal-onset seizures (FOSs) despite treatment with 1 to 3 baseline antiseizure medications (ASMs)?FindingsIn this phase 2b randomized clinical trial including 325 patients with FOSs, treatment with XEN1101 was associated with a statistically significant and robustly dose-dependent decrease in monthly seizure frequency and was generally well tolerated, with adverse effects similar to those of currently available ASMs.MeaningThe findings of this trial support the continued development of XEN1101 for the treatment of FOSs.

Automated summary

This phase 2b clinical trial showed that treatment with XEN1101 led to a significant and dose-dependent reduction in monthly seizure frequency in adults with focal-onset seizures. The results support the further development of XEN1101 for the treatment of FOSs.